Investigational drugs, biological products, and devices; expanded access. (HB2050)
Introduced By
Del. Mark Sickles (D-Alexandria) with support from 6 copatrons, whose average partisan position is:
Those copatrons are Del. Mark Cole (R-Fredericksburg), Del. Patrick Hope (D-Arlington), Del. Kaye Kory (D-Falls Church), Del. Delores McQuinn (D-Richmond), Del. Marcus Simon (D-Falls Church), Sen. Lionell Spruill (D-Chesapeake)
Progress
✓ |
Introduced |
✗ |
Passed Committee |
☐ |
Passed House |
☐ |
Passed Senate |
☐ |
Signed by Governor |
☐ |
Became Law |
Description
Expanded access to investigational drugs, biological products, and devices. Provides that a manufacturer of an investigational drug, biological product, or device may make such drug, product, or device available to a person who has a terminal illness when (i) the person has a terminal condition; (ii) the person has, in consultation with his physician, considered all other treatment options currently approved by the U.S. Food and Drug Administration; (iii) the person's physician has recommended treatment with an investigational drug, biological product, or device; and (iv) the person has provided written informed consent. The bill provides that a manufacturer that provides such drug, product, or device may provide it free of charge or may require the person to pay costs associated with its manufacture. Read the Bill »
Outcome
History
Date | Action |
---|---|
01/14/2015 | Committee |
01/14/2015 | Prefiled and ordered printed; offered 01/14/15 15101266D |
01/14/2015 | Referred to Committee on Health, Welfare and Institutions |
01/20/2015 | Assigned HWI sub: Subcommittee #1 |
01/28/2015 | Impact statement from VDH (HB2050) |
02/11/2015 | Left in Health, Welfare and Institutions |